Literature DB >> 11698395

Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells.

So Hee Kwon1, Seong Hoon Ahn, Yong Kee Kim, Gyu-Un Bae, Jong Woo Yoon, Sungyoul Hong, Hoi Young Lee, Yin-Won Lee, Hyang-Woo Lee, Jeung-Whan Han.   

Abstract

We previously reported that apicidin arrested human cancer cell growth through selective induction of p21(WAF1/Cip1). In this study, the apoptotic potential of apicidin and its mechanism in HL60 cells was investigated. Treatment of HL60 cells with apicidin caused a decrease in viable cell number in a dose-dependent manner and an increase in DNA fragmentation, nuclear morphological change, and apoptotic body formation, concomitant with progressive accumulation of hyperacetylated histone H4. In addition, apicidin converted the procaspase-3 form to catalytically active effector protease, resulting in subsequent cleavages of poly(ADP-ribose) polymerase and p21(WAF1/Cip1). Incubation of HL60 cells with z-DEVD-fmk, a caspase-3 inhibitor, almost completely abrogated apicidin-induced activation of caspase-3, DNA fragmentation, and cleavages of poly(ADP-ribose) polymerase and p21(WAF1/Cip1). Moreover, these effects were preceded by an increase in translocation of Bax into the mitochondria, resulting in the release of cytochrome c and cleavage of procaspase-9. The addition of cycloheximide greatly inhibited activation of caspase-3 by apicidin by interfering with cleavage of procaspase-3 and DNA fragmentation, suggesting that apicidin-induced apoptosis was dependent on de novo protein synthesis. Consistent with these results, apicidin transiently increased the expressions of both Fas and Fas ligand. Preincubation with NOK-1 monoclonal antibody, which prevents the Fas-Fas ligand interaction and is inhibitory to Fas signaling, interfered with apicidin-induced translocation of Bax, cytochrome c release, cleavage of procaspase-3, and DNA fragmentation. Taken together, the results suggest that apicidin might induce apoptosis through selective induction of Fas/Fas ligand, resulting in the release of cytochrome c from the mitochondria to the cytosol and subsequent activation of caspase-9 and caspase-3.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11698395     DOI: 10.1074/jbc.M106699200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

Review 1.  Epigenetic therapy of lymphoma using histone deacetylase inhibitors.

Authors:  Maribel Cotto; Fernando Cabanillas; Maribel Tirado; María V García; Eileen Pacheco
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

Review 2.  Macrocyclic histone deacetylase inhibitors.

Authors:  Sandra C Mwakwari; Vishal Patil; William Guerrant; Adegboyega K Oyelere
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  Quantitative proteomics reveals a role for epigenetic reprogramming during human monocyte differentiation.

Authors:  Dequina Nicholas; Hui Tang; Qiongyi Zhang; Jai Rudra; Feng Xu; William Langridge; Kangling Zhang
Journal:  Mol Cell Proteomics       Date:  2014-10-14       Impact factor: 5.911

4.  The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases.

Authors:  Krithi Rao-Bindal; Nadezhda V Koshkina; John Stewart; Eugenie S Kleinerman
Journal:  Curr Cancer Drug Targets       Date:  2013-05       Impact factor: 3.428

Review 5.  Novel Targets for the Treatment of Melanoma.

Authors:  Lara Ambrosi; Shaheer Khan; Richard D Carvajal; Jessica Yang
Journal:  Curr Oncol Rep       Date:  2019-11-06       Impact factor: 5.075

6.  Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.

Authors:  Margaret A Park; Roland Reinehr; Dieter Häussinger; Christina Voelkel-Johnson; Besim Ogretmen; Adly Yacoub; Steven Grant; Paul Dent
Journal:  Mol Cancer Ther       Date:  2010-08-03       Impact factor: 6.261

7.  Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells.

Authors:  Q Yang; M J Dahl; K H Albertine; R Ramchandran; M Sun; J U Raj
Journal:  Cell Prolif       Date:  2013-12       Impact factor: 6.831

8.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.

Authors:  Margaret A Park; Guo Zhang; Aditi Pandya Martin; Hossein Hamed; Clint Mitchell; Philip B Hylemon; Martin Graf; Mohamed Rahmani; Kevin Ryan; Xiang Liu; Sarah Spiegel; James Norris; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Cancer Biol Ther       Date:  2008-10-12       Impact factor: 4.742

9.  Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Authors:  Jürgen Sonnemann; Linn Dreyer; Maite Hartwig; Chithra D Palani; Le Thi Thu Hong; Ulrike Klier; Barbara Bröker; Uwe Völker; James F Beck
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-08       Impact factor: 4.553

10.  Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.

Authors:  Guo Zhang; Margaret A Park; Clint Mitchell; Hossein Hamed; Mohamed Rahmani; Aditi Pandya Martin; David T Curiel; Adly Yacoub; Martin Graf; Ray Lee; John D Roberts; Paul B Fisher; Steven Grant; Paul Dent
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.